


Atty Docket No.: R0032H-DIV
USSN: 10/731,607

Claim Listing


1 -65. (Canceled)

66. (Previously presented) A compound selected from the group of compounds represented by Formula I:



wherein:

R¹ is a group represented by formula (C):



wherein:

X is N;

R² and R⁴ are each independently in each occurrence:

- (1) hydrogen,
- (2) alkyloxy, or
- (3) halogen;

R⁶ is:

- (1) hydrogen,
- (2) -COR⁹,
- (3) -CONR⁸R⁹,
- (4) -C(V)NR⁸R⁹ wherein V is O or S,

Atty Docket No.: R0032H-DIV
USSN: 10/731,607

(5) $-\text{SO}_2\text{R}^9$, or

(6) $-\text{SO}_2\text{NR}^8\text{R}^9$;

R^8 is independently in each occurrence:

(1) hydrogen,

(2) alkyl, or

(3) hydroxyalkyl;

R^9 is independently in each occurrence:

(1) alkyl,

(2) cycloalkyl,

(3) arylalkyl,

(4) hydroxyalkyl,

(5) haloalkyl,

(6) heterocyclyl,

(7) unsubstituted aryl or mono-, di-, or tri-substituted aryl, the substituents being independently selected from alkyl, halogen, or alkyloxy, or

(8) heteroaryl; or

R^8 and R^9 are taken together with the nitrogen to which they are attached to form a 5- or 6-membered monocyclic saturated or unsaturated ring, and in which the ring is optionally substituted or unsubstituted with oxo; or
a pharmaceutically acceptable salt thereof.

67. (Original) The compound of Claim 66 wherein R^2 and R^4 are each independently in each occurrence hydrogen or halogen.

68. (Original) The compound of Claim 2 wherein R^2 and R^4 are each independently hydrogen, fluoro or chloro.

69. (Previously presented) The compound of Claim 68 wherein the pharmaceutically acceptable salt is selected from hydrochloride, sulfate or oxalate.

Atty Docket No.: R0032H-DIV
USSN: 10/731,607

70. (Previously presented) The compound of Claim 69 wherein the pharmaceutically acceptable salt is sulfate.

71. (Original) The compound of Claim 68 wherein R^8 is hydrogen or alkyl, and R^9 is alkyl or arylalkyl.

72. (Original) The compound of Claim 71 wherein R^8 is hydrogen, methyl, ethyl or propyl, and R^9 is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, *sec*-butyl, *tert*-butyl or arylalkyl.

73. (Original) The compound of Claim 72 wherein R^8 is hydrogen, methyl, ethyl or propyl, and R^9 is alkyl or benzyl.

74 - 83 (Canceled)

84. (Previously presented) A pharmaceutical composition, comprising:
- (a) a compound of claim 66; and
 - (b) a pharmaceutically acceptable carrier.

85. (Previously presented) A method for treating a urinary incontinence disease selected from urge incontinence, stress incontinence, and bladder hyperreactivity, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 66.